The MarketWatch News Department was not involved in the creation of this content. MIRAMAR, Fla., March 25, 2026 /PRNewswire/ -- DifGen Pharmaceuticals and Aveva Drug Delivery Systems today announced a ...
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup ...
The immune system exhibits remarkable plasticity, enabling dynamic responses to environmental cues while maintaining tissue homeostasis. Emerging evidence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results